NEOPHARM, Inc. today announced that it has entered into an exclusive patent license agreement with the National Institutes of Health (NIH) for the development of CINTREDEKIN BESUDOTOX, or IL13-PE38QQR, for the treatment of Pulmonary Fibrosis and asthma
WAUKEGAN, IL, USA | June 11, 2007 | NEOPHARM, Inc. (NASDAQ:NEOL), today announced that it has entered into an exclusive patent license agreement with the National Institutes of Health (NIH) for the development of CINTREDEKIN BESUDOTOX, or IL13-PE38QQR, for the treatment of Pulmonary Fibrosis and asthma.
There are many forms of Pulmonary Fibrosis (PF), one of them, Idiopathic Pulmonary Fibrosis (IPF) also known as Usual Interstitial Pneumonia (UIP), is a progressive disorder affecting approximately 200,000 Americans and over five million people worldwide. With very few treatments currently available for this disease and no known cure, there exists a significant unmet medical need for new therapy options for these patients. According to the estimates of the National Foundation of Pulmonary Fibrosis, about 40,000 Americans die each year of this deadly disease. Currently, the typical treatment consists of systemic steroids to reduce inflammation and immuno-suppressants to attempt to slow disease progression. The disease progression is characterized as the gradual replacement of healthy lung tissue with substantial scarring. The pre-clinical studies performed at NIH, FDA and at University of Michigan, appear to be promising, including preliminary evidence of the reversal of the disease and its scarring in the animal models of IPF when CINTREDEKIN BESUDOTOX is administered as a nebulized product.
"We are excited to announce the signing of this agreement, which we believe will allow NEOPHARM to further capitalize on the intellectual property it has previously developed to work toward developing a suitable and effective treatment option for the millions suffering from this disease," commented Laurence Birch, President and Chief Executive Officer of NEOPHARM. "We believe that the experience we have acquired through our pre-clinical and clinical work with CINTREDEKIN BESUDOTOX should facilitate our development of this drug product candidate for its possible use in the treatment of Pulmonary Fibrosis."
About NEOPHARM, Inc.
NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information can be obtained by visiting NEOPHARM’s Web site at www.neopharm.com.
Forward Looking Statements – This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company’s strategic review of projects and operations, the Company’s drug development programs, the initiation, progress and outcomes of clinical trials of the Company’s drug product candidates, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, regulatory approval, production, and marketing of the Company’s drug and non-drug compounds including, but not limited to the Company’s ability to develop CINTREDEKIN BESUDOTOX as a treatment for Pulmonary Fibrosis (PF) and asthma, uncertainty regarding the outcomes of possible future clinical studies, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug and non-drug compounds, including, but not limited to, CINTREDEKIN BESUDOTOX, that could slow or prevent products coming to market to treat PF or other diseases, uncertainty regarding the Company’s ability to market its drug product candidates, including, but not limited to CINTREDEKIN BESUDOTOX, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release, and in the Company’s most recent annual report on Form 10-K for the calendar year ended December 31, 2006, as updated in its quarterly reports on Form 10-Q. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.
SOURCE: NEOPHARM, Inc.
Post Views: 81
NEOPHARM, Inc. today announced that it has entered into an exclusive patent license agreement with the National Institutes of Health (NIH) for the development of CINTREDEKIN BESUDOTOX, or IL13-PE38QQR, for the treatment of Pulmonary Fibrosis and asthma
WAUKEGAN, IL, USA | June 11, 2007 | NEOPHARM, Inc. (NASDAQ:NEOL), today announced that it has entered into an exclusive patent license agreement with the National Institutes of Health (NIH) for the development of CINTREDEKIN BESUDOTOX, or IL13-PE38QQR, for the treatment of Pulmonary Fibrosis and asthma.
There are many forms of Pulmonary Fibrosis (PF), one of them, Idiopathic Pulmonary Fibrosis (IPF) also known as Usual Interstitial Pneumonia (UIP), is a progressive disorder affecting approximately 200,000 Americans and over five million people worldwide. With very few treatments currently available for this disease and no known cure, there exists a significant unmet medical need for new therapy options for these patients. According to the estimates of the National Foundation of Pulmonary Fibrosis, about 40,000 Americans die each year of this deadly disease. Currently, the typical treatment consists of systemic steroids to reduce inflammation and immuno-suppressants to attempt to slow disease progression. The disease progression is characterized as the gradual replacement of healthy lung tissue with substantial scarring. The pre-clinical studies performed at NIH, FDA and at University of Michigan, appear to be promising, including preliminary evidence of the reversal of the disease and its scarring in the animal models of IPF when CINTREDEKIN BESUDOTOX is administered as a nebulized product.
"We are excited to announce the signing of this agreement, which we believe will allow NEOPHARM to further capitalize on the intellectual property it has previously developed to work toward developing a suitable and effective treatment option for the millions suffering from this disease," commented Laurence Birch, President and Chief Executive Officer of NEOPHARM. "We believe that the experience we have acquired through our pre-clinical and clinical work with CINTREDEKIN BESUDOTOX should facilitate our development of this drug product candidate for its possible use in the treatment of Pulmonary Fibrosis."
About NEOPHARM, Inc.
NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information can be obtained by visiting NEOPHARM’s Web site at www.neopharm.com.
Forward Looking Statements – This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company’s strategic review of projects and operations, the Company’s drug development programs, the initiation, progress and outcomes of clinical trials of the Company’s drug product candidates, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in financing, development, testing, regulatory approval, production, and marketing of the Company’s drug and non-drug compounds including, but not limited to the Company’s ability to develop CINTREDEKIN BESUDOTOX as a treatment for Pulmonary Fibrosis (PF) and asthma, uncertainty regarding the outcomes of possible future clinical studies, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug and non-drug compounds, including, but not limited to, CINTREDEKIN BESUDOTOX, that could slow or prevent products coming to market to treat PF or other diseases, uncertainty regarding the Company’s ability to market its drug product candidates, including, but not limited to CINTREDEKIN BESUDOTOX, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release, and in the Company’s most recent annual report on Form 10-K for the calendar year ended December 31, 2006, as updated in its quarterly reports on Form 10-Q. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results.
SOURCE: NEOPHARM, Inc.
Post Views: 81
